Related Experiment Video
Updated: Jun 20, 2026

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
Published on: September 9, 2025
Restoring leptin sensitivity in metabolic and extra-metabolic leptin resistance: Pharmacologic strategies, systemic
Milan Obradovic1, Sara Khodahemmati1, Sonja Zafirovic1
1Department of Radiobiology and Molecular Genetics, Vin?a Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia.
Abstract:
The presence of leptin resistance is a key barrier to the successful management of obesity. The most recent study has focused on pharmacological drugs that are associated with inflammation and endoplasmic reticulum stress, as well as inhibitors of negative regulators, including PTP1B, SOCS3, and HDAC6, and substances that affect the mTOR and cAMP/Epac/Rap1 signaling pathways. Having an understanding that leptin resistance is caused by defective leptin signaling pathways, such as a disruption in the JAK-STAT pathway or an increase in the expression of SOCS3, shows the difficulty of restoring sensitivity. The physiological implications of leptin resistance extend beyond the regulation of metabolism and can influence the cardiovascular system, the liver (NAFLD/MASLD), the immunological system, the inflammatory system, reproductive health and the neuroendocrine system. The fact that leptin has metabolic impacts on various systems highlights the importance of taking an integrated strategy to treatment procedures. Within the context of metabolic and extra-metabolic leptin resistance, this review provides a summary of recent literature evidence pertaining to the restoration of leptin responsiveness. Also, we include a discussion regarding pharmacologic strategies, systemic implications, and future directions. See also the graphical abstract(Fig. 1).
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Drug Dosing: Obese Patients
Type II Diabetes II: Pathophysiology
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

